Fatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In Vivo

Capasso, Raffaele; Matias, Isabel; Lutz, Beat; Borrelli, Francesca; Capasso, Francesco; Marsicano, Giovanni; Mascolo, Nicola; Petrosino, Stefania; Monory, Krisztina; Valenti, Marta; Marzo, Vincenzo Di; Izzo, Angelo A.

doi:10.1053/j.gastro.2005.06.018

Cited by 115 publications

(162 citation statements)

References 48 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Cannabinoids and endocannabinoid degradation inhibitors decrease intestinal motility, peristalsis, and colonic propulsion in rodents, primarily in a CB 1 -dependent manner [7][8][9][10][11][12]. Accordingly, [8,9,13,14].…”

Section: Role Of the Ecs In Gut Homeostasismentioning

confidence: 99%

“…In this setting, CB 2 agonists might act primarily to inhibit inflammation by acting on CB 2 -expressing cells, instead of preventing their recruitment. Additionally, this observation implies that cannabinoid signaling can be effective in correcting colitis even after its initiation and 10 621 not only at induction of disease. However, seeing as most studies to date used a pre-treatment scheme, further studies in a therapeutic setting are warranted to confirm, or disprove, this effect.…”

mentioning

confidence: 98%

See 1 more Smart Citation

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

Alhouayek

Muccioli

2012

Trends in Molecular Medicine

117

100

View full text Add to dashboard Cite

Section: Role Of the Ecs In Gut Homeostasismentioning

confidence: 99%

mentioning

confidence: 98%

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

Alhouayek

Muccioli

2012

Trends in Molecular Medicine

117

100

View full text Add to dashboard Cite

“…Immunohistochemical studies indicate that the enteric nervous system is the main site of CB1R expression and could be the main site of action for cannabinoids in the gastrointestinal tract (13). Myenteric CB1Rs are physiologically involved in the regulation of gastric and intestinal motility and may constitute a physiological "brake" along the gastrointestinal tract in vivo (15,29,30). Interestingly, CB1R and CB2R are expressed in the epithelium of human colonic tissue (31), and our molecular analysis also revealed CB1R and CB2R gene expression in gastric and small intestine mucosa.…”

Section: Discussionmentioning

confidence: 99%

Acute Activation of Cannabinoid Receptors by Anandamide Reduces Gastrointestinal Motility and Improves Postprandial Glycemia in Mice

et al. 2014

View full text Add to dashboard Cite

The endocannabinoid system (ECS) is associated with an alteration of glucose homeostasis dependent on cannabinoid receptor-1 (CB1R) activation. However, very little information is available concerning the consequences of ECS activation on intestinal glucose absorption. Mice were injected intraperitoneally with anandamide, an endocannabinoid binding both CB1R and CB2R. We measured plasma glucose and xylose appearance after oral loading, gastrointestinal motility, and glucose transepithelial transport using the everted sac method. Anandamide improved hyperglycemia after oral glucose charge whereas glucose clearance and insulin sensitivity were impaired, pointing out some gastrointestinal events. Plasma xylose appearance was delayed in association with a strong decrease in gastrointestinal transit, while anandamide did not alter transporter-mediated glucose absorption. Interestingly, transit was nearly normalized by coinjection of SR141716 and AM630 (CB1R and CB2R antagonist, respectively), and AM630 also reduced the delay of plasma glucose appearance induced by anandamide. When gastric emptying was bypassed by direct glucose administration in the duodenum, anandamide still reduced plasma glucose appearance in wild-type but not in CB1R−/− mice. In conclusion, our findings demonstrated that acute activation of intestinal ECS reduced postprandial glycemia independently on intestinal glucose transport but rather inhibiting gastric emptying and small intestine motility and strongly suggest the involvement of both CB1R and CB2R.

show abstract

“…PEA, an endogenous fatty acid amide, is a congener of the endocannabinoid anandamide belonging to a class of lipid mediators, the family of N-acylethanolamines. PEA has been reported to reduce pain behaviors, and to inhibit somatosensory activation and correlated events in different models of pelvic inflammation [87][88][89][90][91][92][93][94][95][96][97]. Moreover, PEA exerted an antidepressant-like effect comparable to the reference drug fluoxetine [98,99] (Table 2).…”

Section: Depression Inflammation and Pelvic Pain Management: Mcs As mentioning

confidence: 95%

Inflammation and Chronic Pelvic Pain: A Biological Trigger for Depression in Women?

Graziottin¹,

Skaper²,

Fusco³

2014

J Depress Anxiety

View full text Add to dashboard Cite

Fatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In Vivo

Cited by 115 publications

References 48 publications

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

Acute Activation of Cannabinoid Receptors by Anandamide Reduces Gastrointestinal Motility and Improves Postprandial Glycemia in Mice

Inflammation and Chronic Pelvic Pain: A Biological Trigger for Depression in Women?

Contact Info

Product

Resources

About